This side effect is relatively unique to retatrutide and may relate to the glucagon receptor component
Clment K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al
Health Canada says it will review the new study along with others to determine whether safety warnings need to be updated
If this doesnt give a clear result, other tests, like an array comparative genomic hybridization (aCGH), might be needed
Current Wegovy and Zepbound medication information advises patients to report gastrointestinal symptoms that are severe, persistent, or do not go away